Introduction
Prostate cancer represents the second most frequent cancer worldwide, with an incidence of 1.09 million patients in 2012. 1 Although most patients are cured by local treatment, 20%-30% will have a recurrence, especially in bone. Bone metastases often lead to pain or skeletal events (fracture, spinal cord compression) and, therefore, may decrease the patients' quality of life. Radium-223 ( 223 Ra; Xofigo ® ) is an α-emitting radionuclide that, like calcium, is incorporated in the bone matrix at sites of active mineralization via osteoblasts. Therefore, it specifically targets bone metastases. In the Phase III trial ALSYMPCA, 223 Ra showed an overall survival (OS) benefit in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. 2 This led to its approval by the US Food and Drug Administration in 2013. This review, which is the result of a multidisciplinary collaboration by the Intergroupe Coopérateur Francophone de recherche en onco-urologie (ICFuro), discusses the place of 223 Ra in the therapeutic landscape of prostate cancer. It will first describe the mechanism of action of this new agent against bone metastases. It will then summarize the available clinical data and the place of 223 Ra in the current clinical practice. Finally, it will give information on the ongoing trials that assess 223 Ra for prostate cancer management.
Treatment options for metastatic CRPC

Besides 223
Ra, several other agents have shown efficacy in metastatic CRPC (mCRPC). Since 2004, five drugs have been approved for mCRPC treatment, leading to an improvement of progression-free survival and OS. First, docetaxel, a microtubule poison from the taxane family, was approved on the basis of a 2.5-month survival improvement (16.4 vs 18.9 months; P=0.009) compared with mitoxantrone (standard treatment). 3, 4 Then, in 2010, the results of the TROPIC study in a post-docetaxel setting submit your manuscript | www.dovepress.com
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Deshayes et al (OS increase of 2.4 months compared with mitoxantrone; 12.7 vs 15.1 months; P=0.0001) led to the approval of cabazitaxel, a taxane with lower affinity for drug efflux pumps compared with previous molecules of the same class. 5 The same year, it was shown that sipuleucel-T, an autologous cellular immunotherapy, prolongs survival in chemotherapy-naive patients with asymptomatic or minimally symptomatic mCRPC compared with controls (25.8 months in the sipuleucel-T group vs 21.7 months in the placebo group). 6 The last two drugs are "second generation" hormonal treatments that target the androgen receptor signaling pathway. The first one is abiraterone acetate (AA) that targets CYP17A1, a key enzyme involved in androgen synthesis. Its approval relied on a 4-month OS improvement in patients with bone metastatic prostate cancer after docetaxel treatment compared with placebo (15.8 months vs 11.2 months; P,0.0001) and also in chemotherapy-naive patients (34.7 vs 30.3 months; P=0.0033). 7, 8 The second one is enzalutamide, an androgen receptor antagonist. When used as first-line treatment of patients with mCRPC and bone or visceral metastases, enzalutamide improved OS by 2 months compared with placebo (32.4 vs 30.2 months; P,0.001). 9 Similar results were obtained also in a post-docetaxel setting (OS from 13.6 months to 18.4 months; P,0.001). 10 However, despite the introduction of these new molecules for mCRPC clinical management, the right sequence for systemic therapies in advanced prostate cancer is not clearly defined. 11 Although most patients receive second-generation hormonal treatments first, emerging evidence indicates that the most critical issue for patients is to receive at least three different lines of treatment. 12 
Bone metastasis formation
Prostate cancer cells (PCs) have an important tropism for the bone matrix. Experimental studies in animal models showed the role of the primary tumor in preparing the bone matrix for metastasis development. 13, 14 By increasing the activity of growth factors (such as vascular endothelial growth factor-A and placental growth factor), PCs activate bone marrow mesenchymal cells and progenitor endothelial cells to promote the development of a PC host structure with vascularization. Specifically, growth factors create an extracellular matrix prone to receive PCs. Then, osteoblasts, PCs, and other cells in the bone microenvironment secrete a range of additional molecules, such as growth factors (insulin-like growth factor, fibroblast growth factor, transforming growth factor-β), chemokines (CXCL-12, CCL22, and so on) and cytokines (RANKL), that can anchor PCs to the bone matrix. 15, 16 Furthermore, Morris and Edwards reported the potential contribution of both white adipose tissue and bone marrow adipocytes in triggering PC migration and in supporting tumor growth and metastasis formation. 17 Once installed, PCs can affect the bone homeostasis between bone matrix resorption and formation. In most cases, the nature of bone metastases in prostate cancer is osteoblastic. Indeed, histopathological analysis of PC bone metastases demonstrated the presence of a large number of osteoblasts adjacent to PCs, in contrast to normal bone or bone metastases from other cancers. 18 The interaction between the bone microenvironment and PCs creates a vicious circle that favors osteoblastic bone metastases. 19 Indeed, through local and systemic factors, PCs lead to the activation of osteoblast cells. In turn, osteoblasts control bone matrix resorption by activating (through the cytokine RANKL) or inhibiting (through osteoprotegerin) osteoclasts. At the beginning of bone metastasis formation, tumor-derived factors and RANKL-secreting osteoblasts can both activate osteoclasts, leading to bone resorption that subsequently creates more space for the dominant osteoblastic lesions. Thus, cytokines and growth factors released during bone resorption can foster this vicious cycle by facilitating the sustained proliferation of PCs and osteoblasts. Moreover, an increase in serum osteoprotegerin level is also observed in patients with advanced prostate cancer. These findings led Ibrahim et al to propose that osteoblasts play a predominant role in prostate cancer progression in bone through their ability to control PC and osteoclast proliferation. 16 In conclusion, in prostate cancer, bone metastases result from complex interactions between PCs, bone tissue, and bone microenvironment that are regulated by many local and systemic growth factors.
223
Ra mechanism of action
223
Ra is a radioactive isotope that decays to stable lead ( 207 Pb) after a complex disintegration path with several radioactive daughters that produce four alpha particles (Figure 1) . 223 Ra decay chain is as follows: Ra can be produced quite easily and in high amount from elution of an actinium-227/thorium-227 generator system (actinium-227 is produced by neutron irradiation of natural radium-226). 223 Ra physical half-life of 11.4 days allows long-distance shipment. 20 23 Gamma particles are also emitted during 223 Ra disintegration, allowing scintigraphy imaging (eg, for dosimetric studies). After intravenous injection, 223 Ra acts as a calcium analog and about 25% is taken up by bone. It concentrates in sites of active mineralization with high osteoblastic activity (well visualized on bone scans). 24 223 Ra is mainly excreted by the gastrointestinal tract, and ,1% of the injected activity remains in the blood 24 hours after injection. 25 Bone endosteum is the organ with the highest dose (16 Gy) after 223 Ra injection at therapeutic dose (six intravenous injections of 50 kBq/kg 223 Ra chloride for a 70 kg patient), and the corresponding absorbed dose to the red bone marrow is 1.6 Gy. 24 No significant redistribution of 223 Ra radioactive daughters has been observed in preclinical 22 and clinical studies. 223 Ra radiobiological effects are mainly based on the direct damage of tumor cell DNA (nonreparable DNA double-strand breaks, leading to tumor cell death) 27 by alpha particles. Thanks to their high linear energy transfer (LET) (80 keV/µm) and a very short range (,100 micrometers), alpha particles produce a dense ionization around the disintegration site. 23 The high LET leads to cytotoxic effects that are independent of the oxygen concentration; this is particularly interesting in bone (and bone metastases) because it is a quite hypoxic organ.
Clinical results
Different from cytotoxic chemotherapy, 223
Ra dose is not determined based on the patient's body surface area but on his weight, as reported by a Phase II, randomized, doubleblind study that compared three 223 Ra doses (25, 50 , and 80 kBq/kg) administered every 6 weeks for a total of six injections at most. 28 Of note, because of its mechanism of action, 223 Ra biological response is better evaluated by assessing the decrease of alkaline phosphatase (ALP) than prostatespecific antigen (PSA) level. Although the study observed a dose-response relationship, the biological benefit on ALP was not significantly different in the 50 and 80 kBq/kg dose groups. Therefore, the regimen chosen for the Phase III trial was 50 kBq/kg every 6 weeks.
The ALSYMPCA randomized Phase III trial compared 223 Ra efficacy versus placebo in 921 patients with CRPC and 
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Deshayes et al symptomatic bone metastases. 29 This study included only patients with disease progression after or during docetaxel treatment (the only available agent at the time of the trial that showed some OS benefit in mCRPC), or unfit to receive chemotherapy (43% of the enrolled men). Conversely, it excluded patients with visceral metastases. Analysis of the results showed an OS benefit (primary endpoint of the study) in patients treated with 223 Ra injections was not associated with higher risk of adverse events. The quality of life during treatment was evaluated with two self-report questionnaires (EuroQol-5D and FACT-P v4) and was better in patients treated with 223 Ra than in controls. 31 The ALSYMPCA study main limitation was the absence of patients previously or concomitantly treated with new hormonal therapies (NHT), such as abiraterone or enzalutamide, that are now widely used for mCRPC management. A subsequent single-arm Phase III-b trial, conducted to enable early access to 223 Ra before regulatory approval, included patients concomitantly treated with NHT. 32 Moreover, 60% of patients had previously received docetaxel, 40% AA, and 8% enzalutamide. Patients (n=696) received one 223 Ra dose (50 or 55 kBq/kg) every 4 weeks (one to six injections in total). During the trial, 223 Ra was associated with NHT in 223 Ra treatment for mCRPC is not reimbursed in all European countries, although its OS benefit has been demonstrated by the ALSYMPCA trial and robust data about 223 Ra efficacy and safety in combination with NHT have been reported. However, studies with high level of evidence on the optimal sequence of administration of all these treatments are lacking.
Clinical management
The decision to administer 223 Ra should be taken by a multidisciplinary committee that includes at least one oncologist and one nuclear medicine physician. As previously stated, this treatment may be proposed to patients with mCRPC and symptomatic bone metastases but no evidence of visceral metastases. Patients should have a medical consultation with the nuclear medicine physician before starting this treatment in order to check the indication and contraindications based on the clinical, biological, and bone scan data. Moreover, the physician should clearly explain to the patient the expected 223 Ra benefits (mainly on survival and pain relief) and potential side effects. The most relevant side effects reported in studies were related to quality of life (eg, MBq −1 at 1 m immediately after administration. 37 Nuclear medicine services dispensing 223 Ra treatments must comply with the national regulations on radioactive materials. This is the first alpha emitter approved for routine clinical treatment, and health professionals working in nuclear medicine departments (nuclear medicine physicians, physicists, radiopharmacists, and technologists) must be specifically trained. Activity meters must be calibrated with a standard source before treatment initiation. Staff exposure is low, but 223 Ra has to be manipulated carefully with gloves and masks. The main potential issue is internal exposure (ie, accidental 
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Deshayes et al 223 Ra intake by ingestion and/or inhalation). There is no specific procedure for patients' care, except to wear gloves if in contact with fluids/feces ( 223 Ra is mainly excreted with the feces).
223
Ra injected activity (usually below 8 MBq) is very low compared with standard nuclear medicine diagnostic procedures (500-1,000 MBq of technetium-99 m for a bone scan, for example). At the end of the administration, surface contamination should also be checked.
The therapeutic procedure consists in the slow intravenous injection of 55 kBq/kg 223 Ra (about 1 minute), in the department of nuclear medicine, under medical supervision (one injection every 4 weeks for a total of six injections). To avoid the risk of extravasation, the intravenous peripheral blood catheter should be inserted in a large vein by experienced personnel. The ALSYMPCA study did not report any specific reaction at the injection site; however, in the case of 223 Ra extravasation a specific procedure 38 and dermatological follow-up should be proposed. Recently, a possible case of cutaneous cancer was observed after 223 Ra extravasation. 39 After the injection, the patient is monitored for a short time and then he can go home. He needs to follow good hygiene practices for at least 1 week after the injection, including flushing the toilet several times after use, but specific radiation safety precautions are usually not required (like sleeping arrangements or limited time contact with children). The decision to administer the next cycle is based on clinical and biological parameters (platelet count $50*10 9 /L, absolute neutrophil count $1*10 9 /L).
Ra place in therapy
Two studies reported a benefit of 223 Ra on both OS and quality of life in chemotherapy-naive patients with mCRPC and symptomatic bone metastases. 2, 31 Currently, there is no indication for 223 Ra in patients with visceral metastases. Similar results (improved OS, time to biological progression, time to bone progression, pain, and quality of life) were reported in patients with bone metastases and no known visceral metastasis who received docetaxel prior to 223 Ra administration. 32 No published data are available on 223 Ra efficacy in consolidation settings following docetaxel treatment. In conclusion, 223 Ra is recommended only in the absence of visceral metastases.
Several ongoing trials (summarized in Table 3 and full list available at ClinicalTrials.gov) are validating 223 Ra efficacy in 
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Deshayes et al patients with CRPC with bone metastases, alone or in combination with NHT, chemotherapy, or radiation therapy. 
Use in different countries
Conclusion
223 Ra has an original activity, and is the first drug in its class to have demonstrated a significant impact on OS in patients with mCRPC. Therefore, it has enriched the panel of therapeutic options for this disease, together with new-generation hormonal treatments and chemotherapy. Thanks to its relatively good toxicity profile, it could become the best option for a minority of patients with only bone metastases and who are unfit for docetaxel. Unfortunately, this drug is not reimbursed in all western countries. More clinical-economic analyses are needed to confirm the positioning of this novel drug in mCRPC therapeutic armamentarium.
